Abiopharma

🔍 PECK KRISTIN C (Director)

Company: Zoetis Inc. (ZTS)

Report Date: 2026-02-17

Detailed Transactions and Holdings:

• Acquired 20,000 shares of Common Stock at $41.83 per share (Direct)
  Date: 2026-02-17 | Code: M | equity_swap_involved: 0 | shares_owned_after: 121,337.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 9,200 shares of Common Stock at $126.4601 per share (Direct)
  Date: 2026-02-17 | Code: S | equity_swap_involved: 0 | shares_owned_after: 112,137.00 | transaction_form_type: 4 | Footnotes: F2
• Sold 10,800 shares of Common Stock at $127.5492 per share (Direct)
  Date: 2026-02-17 | Code: S | equity_swap_involved: 0 | shares_owned_after: 101,337.00 | transaction_form_type: 4 | Footnotes: F3
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-02-17 | Code: H | nature_of_ownership: 401(k) | shares_owned_after: 833.64 | Footnotes: F4
• Sold 20,000 shares of Stock Option (Derivative)
  Date: 2026-02-17 | Code: M | equity_swap_involved: 0 | shares_owned_after: 249,632.00 | transaction_form_type: 4 | Footnotes: F5, F6, F7, F8, F6
• Holds 84,711 shares of Stock Option at $156.64 per share (Derivative)
  Date: 2026-02-17 | Code: H | shares_owned_after: 84,711.00 | Footnotes: F9, F10, F8
• Holds 62,500 shares of Stock Option at $196.14 per share (Derivative)
  Date: 2026-02-17 | Code: H | shares_owned_after: 62,500.00 | Footnotes: F9, F11, F8
• Holds 67,148 shares of Stock Option at $162.07 per share (Derivative)
  Date: 2026-02-17 | Code: H | shares_owned_after: 67,148.00 | Footnotes: F9, F12, F8

Footnotes:

• F1: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 12, 2025, including for the sale of up to 20,000 shares of Zoetis common stock between January 2, 2026 and February 18, 2026 upon the exercise of certain vested stock options that have an expiration date of February 18, 2026.
• F2: The Price reported in Table I, Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $126.01 to $126.98, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
• F3: The Price reported in Table I, Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $127.01 to $127.56, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
• F4: Represents the common stock equivalents held in the Zoetis Inc. Savings Plan, a 401(k) plan, as of December 31, 2025.
• F5: Stock options (right to buy Zoetis Inc. common stock) granted pursuant to the Zoetis Inc. 2013 Equity and Incentive Plan.
• F6: 32,634 options granted February 14, 2017 at an exercise price of $55.02 per option; 24,642 options granted February 13, 2018 at an exercise price of $73.24 per option; 20,661 options granted February 12, 2019 at an exercise price of $87.51 per option; 55,866 options granted February 11, 2020 at an exercise price of $144.03 per option; 61,078 options granted February 10, 2021 at an exercise price of $160.62 per option; and 54,751 options granted February 8, 2022 at an exercise price of $201.30 per option.
• F7: Each option vests on the third anniversary of the date of grant.
• F8: Each option expires on the tenth anniversary of the date of grant.
• F9: Stock options (right to buy Zoetis Inc. common stock) granted pursuant to the Zoetis Inc. Amended and Restated 2013 Equity and Incentive Plan.
• F10: One-third of each option will vest on the first, second and third anniversaries of the date of grant, February 19, 2025.
• F11: One-third of each option vests on the first, second and third anniversaries of the date of grant, February 6, 2024.
• F12: One-third of each option vests on the first, second and third anniversaries of the date of grant, February 8, 2023.